Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis

2009 ◽  
Vol 89 (6) ◽  
pp. 579-584 ◽  
Author(s):  
Saulius Girnius ◽  
David C. Seldin ◽  
Martha Skinner ◽  
Kathleen T. Finn ◽  
Karen Quillen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
High Dose ◽  
Al Amyloidosis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Short And Long Term ◽  
High Dose Melphalan

scholarly journals Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

Blood ◽  
2015 ◽  
Vol 126 (20) ◽  
pp. 2345-2347 ◽  
Author(s):  
Vaishali Sanchorawala ◽  
Fangui Sun ◽  
Karen Quillen ◽  
J. Mark Sloan ◽  
John L. Berk ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
High Dose ◽  
Al Amyloidosis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
High Dose Melphalan

scholarly journals Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

Blood ◽  
2007 ◽  
Vol 110 (10) ◽  
pp. 3561-3563 ◽  
Author(s):  
Vaishali Sanchorawala ◽  
Martha Skinner ◽  
Karen Quillen ◽  
Kathleen T. Finn ◽  
Gheorghe Doros ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Median Survival ◽  
High Dose ◽  
Al Amyloidosis ◽  
Term Survival ◽  
Long Term Outcome ◽  
High Dose Melphalan

AbstractLong-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.

scholarly journals Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma

2007 ◽  
Vol 13 (8) ◽  
pp. 925-931 ◽  
Author(s):  
John Kuruvilla ◽  
John D. Shepherd ◽  
Heather J. Sutherland ◽  
Thomas J. Nevill ◽  
Janet Nitta ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document